Drugs / Ad5-nCoV-IM
last change May 2023 re-read 2 minutes ago

Ad5-nCoV-IM

also known as IMAd5

Vaccine

Developed for
COVID-19
Investigated by
Seventh Medical Center of PLA General Hospital

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05330871 Apr → Jun 2022 COVID-19 Seventh Medical Center of PLA General Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Ad5-nCoV-IM Ad5-nCoV-IM, 1 dose 0.3ml” NCT05330871
Known as IMAd5 “intramuscular Ad5-nCoV vaccine (IMAd5; 0·3 mL)” PMID 37209700 May 2023
Modality Vaccine “Ad5 COVID-19 Vaccines” NCT05330871
Route Intramuscular “0.3ml intramuscular Ad5-nCoV-IM” NCT05330871